Ann: CE Mark Update, page-245

I think that first approval and therefore first revenues is generally a significant step for bio/medtechs. it's a bit hard to guess what those revenues will be in this case. However the other factor at play here, hopefully, is that revenues will be brought forward by partnering. This company has made encouraging comments regarding partnering, unlike most Australian bio/medtechs that believe they can take their product to market themselves (or at least say they can for the purposes of capital raising and long term employment).
My rough estimate is a market cap of 250 post approval.